U.S. markets closed
  • S&P Futures

    4,239.25
    +7.75 (+0.18%)
     
  • Dow Futures

    33,827.00
    +68.00 (+0.20%)
     
  • Nasdaq Futures

    14,296.25
    +33.25 (+0.23%)
     
  • Russell 2000 Futures

    2,306.70
    +6.40 (+0.28%)
     
  • Crude Oil

    73.20
    +0.12 (+0.16%)
     
  • Gold

    1,778.10
    -5.30 (-0.30%)
     
  • Silver

    25.95
    -0.16 (-0.62%)
     
  • EUR/USD

    1.1935
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • Vix

    16.32
    -0.34 (-2.04%)
     
  • GBP/USD

    1.3966
    +0.0003 (+0.02%)
     
  • USD/JPY

    111.0370
    +0.0750 (+0.07%)
     
  • BTC-USD

    33,583.34
    +1,294.90 (+4.01%)
     
  • CMC Crypto 200

    809.22
    -0.97 (-0.12%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,797.71
    -77.18 (-0.27%)
     

These Top 2 Healthcare Companies Are in a Race to Riches

·6 min read
These Top 2 Healthcare Companies Are in a Race to Riches
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

For patients who go through the rigors of daily insulin shots to treat diabetes, the costs and logistics of adhering to a scheduled plan are a lot to keep up with. In 2020, two top healthcare companies performed admirably during phase 2 trials in a fight to help patients better manage diabetes. Novo Nordisk A/S (NYSE: NVO) and Eli Lilly (NYSE: LLY) both completed separate and successful phase 2 trials of new once-a-week insulin injection products that could potentially be game-changers in the insulin market for patients as well as investors.